{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:07:28Z","timestamp":1777727248369,"version":"3.51.4"},"reference-count":163,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Project of Future Technology Star of Nanjing First Hospital"},{"name":"General Project of Zhejiang Shuren University","award":["Grant No. 2020A11001"],"award-info":[{"award-number":["Grant No. 2020A11001"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82203182"],"award-info":[{"award-number":["82203182"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Despite the availability of multiple treatments for solid tumors, the prognosis of advanced solid tumors remains poor. Antibody\u2013drug conjugates, a novel type of antitumor drugs, which are created by conjugating cytotoxic small-molecule drugs with monoclonal antibodies using well-designed linkers, can selectively deliver effective cytotoxic drugs to tumor cells. Currently, antibody\u2013drug conjugates targeting multiple therapeutic targets for solid tumors are being constantly developed, optimized, and improved, opening up a broad-spectrum antitumor treatment model. However, the use of antibody\u2013drug conjugates is still associated with some limitations that need to be urgently overcome such as poor permeability in solid tumors, notable toxic adverse reactions, and drug resistance. This review mainly discusses the functionality, iteration history, and research progress regarding the use of antibody\u2013drug conjugates in the treatment of common solid tumors and explores possible optimization strategies for the future based on their toxicity, efficacy, and drug resistance, which will ultimately benefit more patients with cancer.<\/jats:p>","DOI":"10.1177\/03000605261434386","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T18:51:41Z","timestamp":1774810301000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical application and optimization strategies for antibody\u2013drug conjugates in solid tumors"],"prefix":"10.1177","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1283-8790","authenticated-orcid":false,"given":"Jie","family":"Qu","sequence":"first","affiliation":[{"name":"Shulan International Medical College, Zhejiang Shuren University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyue","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of oncology, Affiliated Jinling Hospital of Medical School of Nanjing University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linzhu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nanjing First Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wuyou","family":"Cai","sequence":"additional","affiliation":[{"name":"Shulan International Medical College, Zhejiang Shuren University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minfang","family":"Shen","sequence":"additional","affiliation":[{"name":"China Jiliang University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofan","family":"Liu","sequence":"additional","affiliation":[{"name":"Nanjing First Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Wei","sequence":"additional","affiliation":[{"name":"Nanjing First Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Fei","sequence":"additional","affiliation":[{"name":"Nanjing First Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"key":"e_1_3_10_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061845"},{"key":"e_1_3_10_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-01790-6"},{"key":"e_1_3_10_4_2","first-page":"35","article-title":"Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: a phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy","volume":"32","author":"Van Dijk LV","year":"2021","unstructured":"Van Dijk LV, Frank SJ, Yuan Y, et\u00a0al. Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: a phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. Clin Transl Radiat Oncol 2021; 32: 35\u201340.","journal-title":"Clin Transl Radiat Oncol"},{"key":"e_1_3_10_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105115"},{"key":"e_1_3_10_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.01.003"},{"key":"e_1_3_10_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000627"},{"key":"e_1_3_10_8_2","doi-asserted-by":"publisher","DOI":"10.1039\/D5CB00096C"},{"key":"e_1_3_10_9_2","first-page":"11","article-title":"Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing","volume":"8","author":"Larose \u00c9A","year":"2025","unstructured":"Larose \u00c9A, Hua X, Yu S, et\u00a0al. Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing. Cancer Drug Resist 2025; 8: 11.","journal-title":"Cancer Drug Resist"},{"key":"e_1_3_10_10_2","first-page":"4","article-title":"Comparative analysis of the efficacy and safety of antibody\u2011drug conjugates, radionuclide\u2011drug conjugates and their combination targeting claudin 18.2 in gastric cancer treatment","volume":"55","author":"Du H","year":"2026","unstructured":"Du H, Hao XF, Lin BW, et\u00a0al. Comparative analysis of the efficacy and safety of antibody\u2011drug conjugates, radionuclide\u2011drug conjugates and their combination targeting claudin 18.2 in gastric cancer treatment. Oncol Rep 2026; 55: 4.","journal-title":"Oncol Rep"},{"key":"e_1_3_10_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2394"},{"key":"e_1_3_10_12_2","first-page":"1626","article-title":"Effect on mouse leukemia 1210 of a combination by diazo-reaction of amethopterin and gamma-globulins from hamsters inoculated with such leukemia by heterografts]","volume":"246","author":"Mathe G","year":"1958","unstructured":"Mathe G, Tran Ba LOC, Bernard J. [ Effect on mouse leukemia 1210 of a combination by diazo-reaction of amethopterin and gamma-globulins from hamsters inoculated with such leukemia by heterografts]. C R Hebd Seances Acad Sci 1958; 246: 1626\u20131628.","journal-title":"C R Hebd Seances Acad Sci"},{"key":"e_1_3_10_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/55.3.709"},{"key":"e_1_3_10_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/256495a0"},{"key":"e_1_3_10_15_2","first-page":"4354","article-title":"Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen","volume":"41","author":"Goldenberg DM","year":"1981","unstructured":"Goldenberg DM, Gaffar SA, Bennett SJ, et\u00a0al. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res 1981; 41: 4354\u20134360.","journal-title":"Cancer Res"},{"key":"e_1_3_10_16_2","first-page":"2610","article-title":"Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy","volume":"48","author":"Ghetie MA","year":"1988","unstructured":"Ghetie MA, May RD, Till M, et\u00a0al. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res 1988; 48: 2610\u20132617.","journal-title":"Cancer Res"},{"key":"e_1_3_10_17_2","first-page":"4154","article-title":"Phase I clinical comparative study of monoclonal antibody KS1\/4 and KS1\/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma","volume":"50","author":"Elias DJ","year":"1990","unstructured":"Elias DJ, Hirschowitz L, Kline LE, et\u00a0al. Phase I clinical comparative study of monoclonal antibody KS1\/4 and KS1\/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma. Cancer Res 1990; 50: 4154\u20134159.","journal-title":"Cancer Res"},{"key":"e_1_3_10_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1141"},{"key":"e_1_3_10_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8327892"},{"key":"e_1_3_10_20_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0604"},{"key":"e_1_3_10_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00709-2"},{"key":"e_1_3_10_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12517"},{"key":"e_1_3_10_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.04.039"},{"key":"e_1_3_10_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7"},{"key":"e_1_3_10_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00173"},{"key":"e_1_3_10_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031941"},{"key":"e_1_3_10_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01397-y"},{"key":"e_1_3_10_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.06.015"},{"key":"e_1_3_10_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.03.042"},{"key":"e_1_3_10_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107803"},{"key":"e_1_3_10_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-024-01564-3"},{"key":"e_1_3_10_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122910"},{"key":"e_1_3_10_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15082017"},{"key":"e_1_3_10_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0116"},{"key":"e_1_3_10_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8"},{"key":"e_1_3_10_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107078"},{"key":"e_1_3_10_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1500"},{"key":"e_1_3_10_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20051115"},{"key":"e_1_3_10_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206660"},{"key":"e_1_3_10_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2289"},{"key":"e_1_3_10_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1951427"},{"key":"e_1_3_10_42_2","doi-asserted-by":"publisher","DOI":"10.4155\/bio.13.72"},{"key":"e_1_3_10_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822"},{"key":"e_1_3_10_44_2","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c18-00744"},{"key":"e_1_3_10_45_2","first-page":"728","article-title":"AJICAP second generation: improved chemical site-specific conjugation technology for antibody-drug conjugate production","volume":"34","author":"Fujii T","year":"2023","unstructured":"Fujii T, Matsuda Y, Seki T, et\u00a0al. AJICAP second generation: improved chemical site-specific conjugation technology for antibody-drug conjugate production. Bioconjug Chem 2023; 34: 728\u2013738.","journal-title":"Bioconjug Chem"},{"key":"e_1_3_10_46_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1757067"},{"key":"e_1_3_10_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3274"},{"key":"e_1_3_10_48_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0407"},{"key":"e_1_3_10_49_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1274088"},{"key":"e_1_3_10_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102500"},{"key":"e_1_3_10_51_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21705"},{"key":"e_1_3_10_52_2","doi-asserted-by":"publisher","DOI":"10.1177\/11795549241260534"},{"key":"e_1_3_10_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112431"},{"key":"e_1_3_10_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00064-0"},{"key":"e_1_3_10_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01361"},{"key":"e_1_3_10_56_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT248"},{"key":"e_1_3_10_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.9777"},{"key":"e_1_3_10_58_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0215"},{"key":"e_1_3_10_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01476"},{"key":"e_1_3_10_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00159-1"},{"key":"e_1_3_10_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00059"},{"key":"e_1_3_10_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.061"},{"key":"e_1_3_10_63_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8617"},{"key":"e_1_3_10_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2348"},{"key":"e_1_3_10_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102572"},{"key":"e_1_3_10_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(23)00267-8"},{"key":"e_1_3_10_67_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-2911"},{"key":"e_1_3_10_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.582"},{"key":"e_1_3_10_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00656-8"},{"key":"e_1_3_10_70_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4740"},{"key":"e_1_3_10_71_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01459-y"},{"key":"e_1_3_10_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124"},{"key":"e_1_3_10_73_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814017"},{"key":"e_1_3_10_74_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022"},{"key":"e_1_3_10_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02420-5"},{"key":"e_1_3_10_76_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_3_10_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.574"},{"key":"e_1_3_10_78_2","doi-asserted-by":"publisher","DOI":"10.62347\/EMIK7909"},{"key":"e_1_3_10_79_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02044"},{"key":"e_1_3_10_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00468-0"},{"key":"e_1_3_10_81_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"e_1_3_10_82_2","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2025.2525372"},{"key":"e_1_3_10_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01245-X"},{"key":"e_1_3_10_84_2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12214"},{"key":"e_1_3_10_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102415"},{"key":"e_1_3_10_86_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413"},{"key":"e_1_3_10_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00215-2"},{"key":"e_1_3_10_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.12.037"},{"key":"e_1_3_10_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100814"},{"key":"e_1_3_10_90_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.3016"},{"key":"e_1_3_10_91_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.352"},{"key":"e_1_3_10_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00086-3"},{"key":"e_1_3_10_93_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.3501"},{"key":"e_1_3_10_94_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005"},{"key":"e_1_3_10_95_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0452"},{"key":"e_1_3_10_96_2","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302377"},{"key":"e_1_3_10_97_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2488"},{"key":"e_1_3_10_98_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4518"},{"key":"e_1_3_10_99_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-00394-5"},{"key":"e_1_3_10_100_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02044"},{"key":"e_1_3_10_101_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140"},{"key":"e_1_3_10_102_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_3_10_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.11.005"},{"key":"e_1_3_10_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2015.10.002"},{"key":"e_1_3_10_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.01.002"},{"key":"e_1_3_10_106_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004924"},{"key":"e_1_3_10_107_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-1095"},{"key":"e_1_3_10_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.07.017"},{"key":"e_1_3_10_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.01.037"},{"key":"e_1_3_10_110_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01900"},{"key":"e_1_3_10_111_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5507"},{"key":"e_1_3_10_112_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7534"},{"key":"e_1_3_10_113_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw401"},{"key":"e_1_3_10_114_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy023"},{"key":"e_1_3_10_115_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32154"},{"key":"e_1_3_10_116_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2981"},{"key":"e_1_3_10_117_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2962"},{"key":"e_1_3_10_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00056-5"},{"key":"e_1_3_10_119_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15443"},{"key":"e_1_3_10_120_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00720"},{"key":"e_1_3_10_121_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313811"},{"key":"e_1_3_10_122_2","first-page":"A6","article-title":"342 Evaluation of the effectiveness and safety of disitamab vedotin for HER2-expressing recurrent cervical cancer after progression on platinum-based treatment-a single-arm, multicenter, open-label, phase II clinical study","volume":"34","author":"Wu L","year":"2024","unstructured":"Wu L, Li G, Zhang Y, et\u00a0al. 342 Evaluation of the effectiveness and safety of disitamab vedotin for HER2-expressing recurrent cervical cancer after progression on platinum-based treatment-a single-arm, multicenter, open-label, phase II clinical study. International Journal of Gynecological Cancer 2024; 34: A6.","journal-title":"International Journal of Gynecological Cancer"},{"key":"e_1_3_10_123_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075864"},{"key":"e_1_3_10_124_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58009-3"},{"key":"e_1_3_10_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.038"},{"key":"e_1_3_10_126_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.039"},{"key":"e_1_3_10_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31774-X"},{"key":"e_1_3_10_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00674-5"},{"key":"e_1_3_10_129_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00850-2"},{"key":"e_1_3_10_130_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00493-8"},{"key":"e_1_3_10_131_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00013"},{"key":"e_1_3_10_132_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3595"},{"key":"e_1_3_10_133_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2267975"},{"key":"e_1_3_10_134_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00783-w"},{"key":"e_1_3_10_135_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9080872"},{"key":"e_1_3_10_136_2","doi-asserted-by":"publisher","DOI":"10.3390\/antib10040042"},{"key":"e_1_3_10_137_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0375"},{"key":"e_1_3_10_138_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172156"},{"key":"e_1_3_10_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.10.007"},{"key":"e_1_3_10_140_2","first-page":"12929","article-title":"Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery","volume":"24","author":"Li L","year":"2020","unstructured":"Li L, Xu MZ, Wang L, et\u00a0al. Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery. Eur Rev Med Pharmacol Sci 2020; 24: 12929\u201312937.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_10_141_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00050-07"},{"key":"e_1_3_10_142_2","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.201900178"},{"key":"e_1_3_10_143_2","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2024.12542"},{"key":"e_1_3_10_144_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-024-1072-8"},{"key":"e_1_3_10_145_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203517"},{"key":"e_1_3_10_146_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15082020"},{"key":"e_1_3_10_147_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.1c00134"},{"key":"e_1_3_10_148_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00106"},{"key":"e_1_3_10_149_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0875"},{"key":"e_1_3_10_150_2","first-page":"77","article-title":"Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies","volume":"3","author":"Dvorak HF","year":"1991","unstructured":"Dvorak HF, Nagy JA, Dvorak AM. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 1991; 3: 77\u201385.","journal-title":"Cancer Cells"},{"key":"e_1_3_10_151_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1171362"},{"key":"e_1_3_10_152_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2233"},{"key":"e_1_3_10_153_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2011.12.010"},{"key":"e_1_3_10_154_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30569"},{"key":"e_1_3_10_155_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI120481"},{"key":"e_1_3_10_156_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0099"},{"key":"e_1_3_10_157_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020447"},{"key":"e_1_3_10_158_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.539527"},{"key":"e_1_3_10_159_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0103"},{"key":"e_1_3_10_160_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01509-2"},{"key":"e_1_3_10_161_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-071322-065903"},{"key":"e_1_3_10_162_2","doi-asserted-by":"publisher","DOI":"10.7150\/thno.98178"},{"key":"e_1_3_10_163_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03600-2"},{"key":"e_1_3_10_164_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102395"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605261434386","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03000605261434386","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605261434386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:48:58Z","timestamp":1777459738000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03000605261434386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":163,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/03000605261434386"],"URL":"https:\/\/doi.org\/10.1177\/03000605261434386","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"03000605261434386"}}